Korean J Gastroenterol.  2014 Feb;63(2):66-81. 10.4166/kjg.2014.63.2.66.

Synopsis on Clinical Practice Guideline of Gastric Cancer in Korea: An Evidence-Based Approach

• Lee JH
• Kim JG
• Jung HK
• Kim JH
• Jeong WK
• Jeon TJ
• Kim JM
• Kim YI
• Ryu KW
• Kong SH
• Kim HI
• Jung HY
• Kim YS
• Zang DY
• Cho JY
• Park JO
• Lim DH
• Jung ES
• Ahn HS
• Kim HJ

• KMID: 1730913
• DOI: http://doi.org/10.4166/kjg.2014.63.2.66

Abstract

Although, gastric cancer is quite common in Korea, the treatment outcome is relatively favorable compared to that of Western countries. However, there is no Korean multidisciplinary guideline for gastric cancer and thus, a guideline adequate for domestic circumstances is required. Experts from related societies developed 22 recommendation statements for the diagnosis (n=9) and treatment (n=13) based on relevant key questions. Evidence levels based on systematic review of literatures were classified as five levels from A to E, and recommendation grades were classified as either strong or weak. The topics of this guideline cover diagnostic modalities (endoscopy, endoscopic ultrasound, radiologic diagnosis), treatment modalities (surgery, therapeutic endoscopy, chemotherapy, radiotherapy) and pathologic evaluation. External review of the guideline was conducted at the finalization phase.

Keyword

Stomach neoplasms; Guidelines

MeSH Terms

Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Chemoradiotherapy, Adjuvant
Endoscopy, Gastrointestinal
Endosonography
Evidence-Based Medicine
Follow-Up Studies
Gastrectomy
Humans
Magnetic Resonance Imaging
Positron-Emission Tomography
Republic of Korea
Stomach Neoplasms/*diagnosis/pathology/therapy
Tomography, X-Ray Computed

Reference

References

1. Cancer statistics. [Internet]. Goyang (Korea): National Cancer information Center [cited 2014 Feb 5]. Available from:. http://www.cancer.go.kr/mbs/cancer/subview.jsp?id=cancer_040101000000.

2. Cause of death statistics. [Internet]. Daejeon (Korea): Korean Statistical Information Service [cited 2014 Feb 5]. Available from:. http://kosis.kr/index/index.jsp.

3. Deeks JJ, Dinnes J, D'Amico R, et al. International Stroke Trial Collaborative Group; European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies. Health Technol Assess. 2003; 7:iii–x. 1-173.

4. Turk DJ, Kozarek RA, Botoman VA, Patterson DJ, Ball TJ. Disposable endoscopic biopsy forceps: comparison with standard forceps of sample size and adequacy of specimen. J Clin Gastroenterol. 1991; 13:76–78.

5. Dandalides SM, Carey WD, Petras R, Achkar E. Endoscopic small bowel mucosal biopsy: a controlled trial evaluating forceps size and biopsy location in the diagnosis of normal and abnormal mucosal architecture. Gastrointest Endosc. 1989; 35:197–200.

6. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003; 3:25.

7. Yang R, Vuitch F, Wright K, McCarthy J. Adequacy of disposable biopsy forceps for gastrointestinal endoscopy: a direct compar-choice between total and proximal gastrectomy in proximal early gastric cancer. Am J Surg. 2008; 196:587–591.

8. Guyatt GH, Oxman AD, Kunz R, et al. GRADE Working Group. Incorporating considerations of resources use into grading recommendations. BMJ. 2008; 336:1170–1173.

9. Kobayashi S, Kasugai T, Yamazaki H. Endoscopic differentiation of early gastric cancer from benign peptic ulcer. Gastrointest Endosc. 1979; 25:55–57.

10. Ryu KW, Lee JH, Choi IJ, Bae JM. Preoperative endoscopic clipping: localizing technique of early gastric cancer. J Surg Oncol. 2003; 82:75–77.

11. Park DJ, Lee HJ, Kim SG, et al. Intraoperative gastroscopy for gastric surgery. Surg Endosc. 2005; 19:1358–1361.

12. Shim CS. Staining in gastrointestinal endoscopy: clinical appli-cations and limitations. Endoscopy. 1999; 31:487–496.

13. Mocellin S, Marchet A, Nitti D. EUS for the staging of gastric cancer: a meta-analysis. Gastrointest Endosc. 2011; 73:1122–1134.

14. Choi J, Kim SG, Im JP, Kim JS, Jung HC, Song IS. Comparison of endoscopic ultrasonography and conventional endoscopy for prediction of depth of tumor invasion in early gastric cancer. Endoscopy. 2010; 42:705–713.

15. Low VH, Levine MS, Rubesin SE, Laufer I, Herlinger H. Diagnosis of gastric carcinoma: sensitivity of double-contrast barium studies. AJR Am J Roentgenol. 1994; 162:329–334.

16. Murakami R, Tsukuma H, Ubukata T, et al. Estimation of validity of mass screening program for gastric cancer in Osaka, Japan. Cancer. 1990; 65:1255–1260.

17. Gelfand DW. The multiphasic upper gastrointestinal exami-nation. Radiol Clin North Am. 1994; 32:1067–1081.

18. Chen CY, Hsu JS, Wu DC, et al. Gastric cancer: preoperative local staging with 3D multi-detector row CT–correlation with surgical and histopathologic results. Radiology. 2007; 242:472–482.

19. Kim JH, Eun HW, Hong SS, Auh YH. Early gastric cancer: virtual gastroscopy. Abdominal Imaging. 2006; 31:507–513.

20. Kim HJ, Kim AY, Oh ST, et al. Gastric cancer staging at multi-de-tector row CT gastrography: comparison of transverse and volu-metric CT scanning. Radiology. 2005; 236:879–885.

21. Kumano S, Murakami T, Kim T, et al. T staging of gastric cancer: role of multi-detector row CT. Radiology. 2005; 237:961–966.

22. Makino T, Fujiwara Y, Takiguchi S, et al. Preoperative T staging of gastric cancer by multi-detector row computed tomography. Surgery. 2011; 149:672–679.

23. Park SR, Kim MJ, Ryu KW, et al. Prognostic value of pre-operative clinical staging assessed by computed tomography in resectable gastric cancer patients: a viewpoint in the era of preoperative treatment. Ann Surg. 2010; 251:428–435.

24. Yan C, Zhu ZG, Yan M, et al. Value of multidetector-row computed tomography in the preoperative T and N staging of gastric carcinoma: a large-scale Chinese study. J Surg Oncol. 2009; 100:205–214.

25. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228–247.

26. Goshima S, Kanematsu M, Watanabe H, et al. Hepatic he-mangioma and metastasis: differentiation with gadoxetate disodium-enhanced 3-T MRI. AJR Am J Roentgenol. 2010; 195:941–946.

27. Shoda H, Kakugawa Y, Saito D, et al. Evaluation of 18F-2-de-oxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. Br J Cancer. 2007; 97:1493–1498.

28. Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am. 2001; 39:883–917.

29. Yoshioka T, Yamaguchi K, Kubota K, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med. 2003; 44:690–699.

30. Buyyounouski MK, Klump WJ, Konski A, Wu H, Adler LP. FDG PET imaging of signet-ring cell adenocarcinoma of the stomach. Clin Nucl Med. 2005; 30:118–119.

31. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg. 2004; 28:247–253.

32. Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 2003; 30:288–295.

33. De Potter T, Flamen P, Van Cutsem E, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging. 2002; 29:525–529.

34. Yun M, Lim JS, Noh SH, et al. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. J Nucl Med. 2005; 46:1582–1588.

35. Hillner BE, Siegel BA, Shields AF, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med. 2008; 49:1928–1935.

36. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002; 224:748–756.

37. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med. 2003; 44:1407–1412.

38. Jadvar H, Tatlidil R, Garcia AA, Conti PS. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol. 2003; 58:215–221.

39. Ott K, Fink U, Becker K, et al. Prediction of response to pre-operative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003; 21:4604–4610.

40. Bilici A, Ustaalioglu BB, Seker M, et al. The role of ¹⁸ F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making? Eur J Nucl Med Mol Imaging. 2011; 38:64–73.

41. Harrison LE, Karpeh MS, Brennan MF. Total gastrectomy is not necessary for proximal gastric cancer. Surgery. 1998; 123:127–130.

42. An JY, Youn HG, Choi MG, Noh JH, Sohn TS, Kim S. The difficult testinal Surgery Study (KLASS) Group. Recurrence following laparoscopy-assisted gastrectomy for gastric cancer: a multicenter retrospective analysis of 1,417 patients. Ann Surg Oncol. 2010; 17:1777–1786.

43. Ooki A, Yamashita K, Kikuchi S, et al. Clinical significance of total gastrectomy for proximal gastric cancer. Anticancer Res. 2008; 28:2875–2883.

44. Yoo CH, Sohn BH, Han WK, Pae WK. Proximal gastrectomy re-constructed by jejunal pouch interposition for upper third gastric cancer: prospective randomized study. World J Surg. 2005; 29:1592–1599.

45. The Korean Gastric Cancer Association. Gastric cancer and gastrointestinal disease. Seoul: Ilchokak;2011.

46. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011; 14:113–123.

47. Sasako M, Sano T, Yamamoto S, et al. Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008; 359:453–462.

48. Nunobe S, Hiki N, Ohyama S, Fukunaga T, Seto Y, Yamaguchi T. Survival benefits of pancreatoduodenectomy for gastric cancer: relationship to the number of lymph node metastases. Langenbecks Arch Surg. 2008; 393:157–162.

49. Shchepotin IB, Chorny VA, Nauta RJ, Shabahang M, Buras RR, Evans SR. Extended surgical resection in T4 gastric cancer. Am J Surg. 1998; 175:123–126.

50. Maehara Y, Oiwa H, Tomisaki S, et al. Prognosis and surgical treatment of gastric cancer invading the pancreas. Oncology. 2000; 59:1–6.

51. Mita K, Ito H, Fukumoto M, et al. Surgical outcomes and survival after extended multiorgan resection for T4 gastric cancer. Am J Surg. 2012; 203:107–111.

52. Ozer I, Bostanci EB, Orug T, et al. Surgical outcomes and survival after multiorgan resection for locally advanced gastric cancer. Am J Surg. 2009; 198:25–30.

53. Jeong O, Choi WY, Park YK. Appropriate selection of patients for combined organ resection in cases of gastric carcinoma invading adjacent organs. J Surg Oncol. 2009; 100:115–120.

54. Carboni F, Lepiane P, Santoro R, et al. Extended multiorgan re-section for T4 gastric carcinoma: 25-year experience. J Surg Oncol. 2005; 90:95–100.

55. Oñate-Ocaña LF, Becker M, Carrillo JF, et al. Selection of best candidates for multiorgan resection among patients with T4 gastric carcinoma. J Surg Oncol. 2008; 98:336–342.

56. Kobayashi A, Nakagohri T, Konishi M, et al. Aggressive surgical treatment for T4 gastric cancer. J Gastrointest Surg. 2004; 8:464–470.

57. Kunisaki C, Akiyama H, Nomura M, et al. Surgical outcomes in patients with T4 gastric carcinoma. J Am Coll Surg. 2006; 202:223–230.

58. Martin RC 2nd, Jaques DP, Brennan MF, Karpeh M. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. Ann Surg. 2002; 236:159–165.

59. Shin SH, Jung H, Choi SH, et al. Clinical significance of splenic hilar lymph node metastasis in proximal gastric cancer. Ann Surg Oncol. 2009; 16:1304–1309.

60. Sano T, Yamamoto S, Sasako M. Japan Clinical Oncology Group Study LCOG 0110-MF. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF. Jpn J Clin Oncol. 2002; 32:363–364.

61. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg. 2006; 93:559–563.

62. Kunisaki C, Makino H, Suwa H, et al. Impact of splenectomy in patients with gastric adenocarcinoma of the cardia. J Gastrointest Surg. 2007; 11:1039–1044.

63. Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH. Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer. Gynecol Oncol. 2004; 94:477–482.

64. Okano K, Maeba T, Ishimura K, et al. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg. 2002; 235:86–91.

65. Cheon SH, Rha SY, Jeung HC, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol. 2008; 19:1146–1153.

66. Glehen O, Mithieux F, Osinsky D, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyper-thermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol. 2003; 21:799–806.

67. Chareton B, Landen S, Manganas D, Meunier B, Launois B. Prospective randomized trial comparing Billroth I and Billroth II procedures for carcinoma of the gastric antrum. J Am Coll Surg. 1996; 183:190–194.

68. Kang KC, Cho GS, Han SU, et al. Korean Laparoscopic Gastrointestinal Surgery Study (KLASS) Group. Comparison of Billroth I and Billroth II reconstructions after laparoscopy-assisted distal gastrectomy: a retrospective analysis of large-scale multicenter results from Korea. Surg Endosc. 2011; 25:1953–1961.

69. Kojima K, Yamada H, Inokuchi M, Kawano T, Sugihara K. A comparison of Roux-en-Y and Billroth-I reconstruction after laparo-scopy-assisted distal gastrectomy. Ann Surg. 2008; 247:962–967.

70. Kim JP, Hur YS, Yang HK. Lymph node metastasis as a significant prognostic factor in early gastric cancer: analysis of 1,136 early gastric cancers. Ann Surg Oncol. 1995; 2:308–313.

71. An JY, Baik YH, Choi MG, Noh JH, Sohn TS, Kim S. Predictive factors for lymph node metastasis in early gastric cancer with submucosal invasion: analysis of a single institutional experience. Ann Surg. 2007; 246:749–753.

72. Lai JF, Kim S, Kim K, et al. Prediction of recurrence of early gastric cancer after curative resection. Ann Surg Oncol. 2009; 1:1896–1902.

73. Youn HG, An JY, Choi MG, Noh JH, Sohn TS, Kim S. Recurrence after curative resection of early gastric cancer. Ann Surg Oncol. 2010; 17:448–454.

74. Kim MC, Kim W, Kim HH, et al. Korean Laparoscopic Gastrointestinal Surgery Study (KLASS) Group. Risk factors associated with complication following laparoscopy-assisted gastrectomy for gastric cancer: a large-scale korean multicenter study. Ann Surg Oncol. 2008; 15:2692–2700.

75. Song J, Lee HJ, Cho GS, et al. Korean Laparoscopic Gastroin-ison with reusable forceps. Gastrointest Endosc. 1990; 36:379–381.

76. Kitano S, Shiraishi N, Uyama I, Sugihara K, Tanigawa N. Japanese Laparoscopic Surgery Study Group. A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. Ann Surg. 2007; 245:68–72.

77. Huscher CG, Mingoli A, Sgarzini G, et al. Totally laparoscopic total and subtotal gastrectomy with extended lymph node dissection for early and advanced gastric cancer: early and long-term results of a 100-patient series. Am J Surg. 2007; 194:839–844.

78. Fujiwara M, Kodera Y, Misawa K, et al. Longterm outcomes of early-stage gastric carcinoma patients treated with laparo-scopy-assisted surgery. J Am Coll Surg. 2008; 206:138–143.

79. Hwang SH, Park do J, Jee YS, et al. Actual 3-year survival after laparoscopy-assisted gastrectomy for gastric cancer. Arch Surg. 2009; 144:559–564.

80. Lee SW, Nomura E, Bouras G, Tokuhara T, Tsunemi S, Tanigawa N. Long-term oncologic outcomes from laparoscopic gastrectomy for gastric cancer: a single-center experience of 601 consecutive resections. J Am Coll Surg. 2010; 211:33–40.

81. Pugliese R, Maggioni D, Sansonna F, et al. Subtotal gastrectomy with D2 dissection by minimally invasive surgery for distal adenocarcinoma of the stomach: results and 5-year survival. Surg Endosc. 2010; 24:2594–2602.

82. Jiang X, Hiki N, Nunobe S, et al. Long-term outcome and survival with laparoscopy-assisted pylorus-preserving gastrectomy for early gastric cancer. Surg Endosc. 2011; 25:1182–1186.

83. Yoo HM, Lee HH, Shim JH, et al. Long-term outcomes and survival after laparoscopy-assisted distal gastrectomy for gastric cancer: three-year survival analysis of a single-center experience in Korea. J Surg Oncol. 2011; 104:511–515.

84. Pak KH, Hyung WJ, Son T, et al. Long-term oncologic outcomes of 714 consecutive laparoscopic gastrectomies for gastric cancer: results from the 7-year experience of a single institute. Surg Endosc. 2012; 26:130–136.

85. Hur H, Jeon HM, Kim W. Laparoscopy-assisted distal gastrectomy with D2 lymphadenectomy for T2b advanced gastric cancers: three years' experience. J Surg Oncol. 2008; 98:515–519.

86. Kim HH, Hyung WJ, Cho GS, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report–a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg. 2010; 251:417–420.

87. Sano T. Evaluation of the gastric cancer treatment guidelines of the Japanese Gastric Cancer Association. Gan To Kagaku Ryoho. 2010; 37:582–586.

88. Sasaki T. Discussion for gastric cancer treatment guidelines in Japan. Nihon Rinsho. 2003; 61:13–18.

89. Kahlke V, Bestmann B, Schmid A, Doniec JM, Küchler T, Kremer B. Palliation of metastatic gastric cancer: impact of pre-operative symptoms and the type of operation on survival and quality of life. World J Surg. 2004; 28:369–375.

90. Sarela AI, Yelluri S. Leeds Upper Gastrointestinal Cancer Multidisciplinary Team. Gastric adenocarcinoma with distant metastasis: is gastrectomy necessary? Arch Surg. 2007; 142:143–149.

91. Ono H, Kondo H, Gotoda T, et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut. 2001; 48:225–229.

92. Manner H, Rabenstein T, May A, et al. Long-term results of endoscopic resection in early gastric cancer: the Western experience. Am J Gastroenterol. 2009; 104:566–573.

93. Choi KS, Jung HY, Choi KD, et al. EMR versus gastrectomy for intramucosal gastric cancer: comparison of long-term outcomes. Gastrointest Endosc. 2011; 73:942–948.

94. Jang JS, Choi SR, Qureshi W, et al. Long-term outcomes of endoscopic submucosal dissection in gastric neoplastic lesions at a single institution in South Korea. Scand J Gastroenterol. 2009; 44:1315–1322.

95. Uedo N, Iishi H, Tatsuta M, et al. Longterm outcomes after endoscopic mucosal resection for early gastric cancer. Gastric Cancer. 2006; 9:88–92.

96. Gotoda T, Iwasaki M, Kusano C, Seewald S, Oda I. Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. Br J Surg. 2010; 97:868–871.

97. Bennett C, Wang Y, Pan T. Endoscopic mucosal resection for early gastric cancer. Cochrane Database Syst Rev. 2009; 4:CD004276.

98. Chung JW, Jung HY, Choi KD, et al. Extended indication of endoscopic resection for mucosal early gastric cancer: analysis of a single center experience. J Gastroenterol Hepatol. 2011; 26:884–887.

99. Kang HJ, Kim DH, Jeon TY, et al. Lymph node metastasis from intestinal-type early gastric cancer: experience in a single institution and reassessment of the extended criteria for endoscopic submucosal dissection. Gastrointest Endosc. 2010; 72:508–515.

100. Soetikno R, Kaltenbach T, Yeh R, Gotoda T. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. J Clin Oncol. 2005; 23:4490–4498.

101. Song SY, Park S, Kim S, Son HJ, Rhee JC. Characteristics of intramucosal gastric carcinoma with lymph node metastatic disease. Histopathology. 2004; 44:437–444.

102. Hyung WJ, Cheong JH, Kim J, Chen J, Choi SH, Noh SH. Application of minimally invasive treatment for early gastric cancer. J Surg Oncol. 2004; 85:181–185.

103. Lee H, Yun WK, Min BH, et al. A feasibility study on the expanded indication for endoscopic submucosal dissection of early gastric cancer. Surg Endosc. 2011; 25:1985–1993.

104. Ahn JY, Jung HY, Choi KD, et al. Endoscopic and oncologic outcomes after endoscopic resection for early gastric cancer: 1370 cases of absolute and extended indications. Gastrointest Endosc. 2011; 74:485–493.

105. Ajani JA, Barthel JS, Bekaii-Saab T, et al. NCCN Gastric Cancer Panel. Gastric cancer. J Natl Compr Canc Netw. 2010; 8:378–409.

106. Roviello F, Marrelli D, de Manzoni G, et al. Italian Research Group for Gastric Cancer. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003; 90:1113–1119.

107. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000; 87:236–242.

108. Earle CC, Maroun JA. Adjuvant chemotherapy after curative re-section for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer. 1999; 35:1059–1064.

109. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-anal-ysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol. 2000; 11:837–843.

110. Paoletti X, Oba K, Burzykowski T, et al. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010; 303:1729–1737.

111. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355:11–20.

112. Sakuramoto S, Sasako M, Yamaguchi T, et al. ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357:1810–1820.

113. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011; 29:4387–4393.

114. Bang YJ, Kim YW, Yang HK, et al. CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012; 379:315–321.

115. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006; 24:2903–2909.

116. Glimelius B, Ekström K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997; 8:163–168.

117. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993; 72:37–41.

118. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995; 71:587–591.

119. Cocconi G, DeLisi V, Di Blasio B. Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep. 1982; 66:1263–1266.

120. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985; 253:2061–2067.

121. Douglass HO Jr, Lavin PT, Goudsmit A, Klaassen DJ, Paul AR. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorour-acil in advanced measurable gastric cancer (EST 2277). J Clin Oncol. 1984; 2:1372–1381.

122. O'Connel MJ. The Gastrointestinal Tumor Study Group. A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma. Cancer. 1982; 49:1362–1366.

123. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gas-tro-oesophageal junction cancer (ToGA): a phase 3, open-la-bel, randomised controlled trial. Lancet. 2010; 376:687–697.

124. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011; 29:3968–3976.

125. Lordick F, Kang YK, Salman P, et al. Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study. J Clin Oncol. 2013; 31(Suppl):abstr #4021.

126. Hecht JR, Bang YJ, Qin S, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. J Clin Oncol. 2013; 31(Suppl):abstr #LBA4001.

127. Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival ad-vantage for irinotecan versus best supportive care as sec-ond-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011; 47:2306–2314.

128. Park SH, Lim DH, Park K, et al. A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC). J Clin Oncol. 2011; 29(Suppl):abstr #4004.

129. Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang DW, Zhang RG. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)–report on 370 patients. Int J Radiat Oncol Biol Phys. 1998; 42:929–934.

130. Skoropad VY, Berdov BA, Mardynski YS, Titova LN. A prospective, randomized trial of pre-operative and intraoperative radiotherapy versus surgery alone in resectable gastric cancer. Eur J Surg Oncol. 2000; 26:773–779.

131. Skoropad V, Berdov B, Zagrebin V. Concentrated preoperative radiotherapy for resectable gastric cancer: 20-years follow-up of a randomized trial. J Surg Oncol. 2002; 80:72–78.

132. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345:725–730.

133. Kim S, Lim DH, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005; 63:1279–1285.

134. Dikken JL, Jansen EP, Cats A, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010; 28:2430–2436.

135. The Study Group for Gastrointestinal Pathology, Korean Society of Pathologists. Guidelines for Pathologic Study of Gastric Cancer. Korean J Pathol. 1992; 26:154–163.

136. International Agency for Research on Cancer. WHO classification of tumors of the digestive system. 4th ed. Lyon: World Health Organization;2010.

137. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965; 64:31–49.

138. Kim WH, Park CK, Kim YB, et al. A standardized pathology report for gastric cancer. Korean J Pathol. 2005; 39:106–113.

139. Edge SB. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed.New York: Springer;2010.

140. Kim A, Bae JM, Kim SW, Gu MJ, Bae YK. HER2 status in gastric adenocarcinomas assessed by immunohistochemistry, auto-mated silver-enhanced in situ hybridization and fluorescence in situ hybridization. Korean J Pathol. 2010; 44:493–501.

141. Kim MA, Jung EJ, Lee HS, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol. 2007; 38:1386–1393.

142. Bilous M, Osamura RY, Rüschoff J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2010; 41:304–305.

143. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52:797–805.

144. Yano T, Doi T, Ohtsu A, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 2006; 15:65–71.